Q-omics provides the consensus-scored TMEM220 profile across patient tissues and cancer cell-line models. TMEM220 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM220 is differentially expressed in 17, with the highest sampling consensus in THCA. Additionally, TMEM220 RNA expression shows 19,439 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where TMEM220 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM220 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM220 survival associations across molecular data types. TMEM220 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM220 RNA expression–survival associations across cancer types. High TMEM220 expression shows unfavorable associations in LUSC and SKCM, but favorable associations in KIRC, HNSC, UVM and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM220 RNA expression.
This table summarizes TMEM220 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM220. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM220 shows lower tumor expression in THCA, COAD, BLCA, KICH, LUAD and HNSC. The THCA box plot shows higher TMEM220 RNA expression in normal versus tumor tissue (log2 FC = −2.875, t-test p < 0.001).
This table shows molecular features associated with TMEM220 in patient tissues and cancer cell lines. In patient samples, TMEM220 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM220 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
